[SCHEDULE 13D/A] Stoke Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Skorpios Trust, Montrago Trustees Ltd, Ezbon International Ltd and Blue Horizon Enterprise Ltd filed Amendment No. 6 to their Schedule 13D for Stoke Therapeutics (STOK). The amendment reports that on August 22, 2025 Blue Horizon sold 1,000,000 shares of common stock in an open-market transaction at $18.50 per share. The filing states that, following that sale, the Reporting Persons ceased to be beneficial owners of more than 5.0% of the outstanding shares, based on 54,797,418 shares outstanding. The amendment incorporates updated cover page figures showing individual shared voting and dispositive power and adds a joint filing agreement as an exhibit.

Positive

• None.

Negative

• Blue Horizon sold 1,000,000 shares in an open-market transaction at $18.50 per share, reducing reporting group's influence.
• Reporting Persons ceased to be beneficial owners of more than 5% of Stoke Therapeutics on August 22, 2025, changing disclosure/engagement status.

Insights

Corporate Governance Expert

TL;DR: A coordinated holder reduced its stake below the 5% reporting threshold after a 1,000,000-share sale, altering disclosure status.

The amendment documents a deliberate open-market sale by Blue Horizon that materially changed the Reporting Persons' disclosure obligations by reducing aggregate holdings below 5% of common stock. That change ends certain Schedule 13D implications tied to >5% ownership, including heightened market attention and potential activism signaling. The filing is procedural but material from a disclosure standpoint because it affects monitoring and potential engagement expectations between the holders and Stoke Therapeutics' management.

Financial Analyst

TL;DR: Reporting Persons sold 1,000,000 shares at $18.50, reducing combined stake under 5%, a noteworthy but non-crisis development.

This sale generated proceeds of approximately $18.5 million for Blue Horizon and lowered the group's combined beneficial ownership to below the 5% threshold referenced in the filing. The disclosure clarifies share counts and voting/dispositive power figures for each reporting entity, aiding investors' understanding of ownership concentration. No other transactions in the past 60 days were reported.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

Stoke Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

86150R107

(CUSIP Number)

Patrik Blochlinger, Chief Lega
Rigmora (Switzerland) Ltd, Stockerstrasse 8
Zurich, V8, 8002
41 44 287 2498

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/22/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 86150R107

1

Name of reporting person

Blue Horizon Enterprise Ltd

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,967,621.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,967,621.00

11

Aggregate amount beneficially owned by each reporting person

1,967,621.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

The percentages used herein and in the rest of this Schedule 13D are calculated based upon 54,797,418 shares of the Issuer's common stock outstanding as of July 31, 2025, as reported in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025.

SCHEDULE 13D

CUSIP No. 86150R107

1

Name of reporting person

Ezbon International Ltd

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 288,560.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 288,560.00

11

Aggregate amount beneficially owned by each reporting person

288,560.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.5 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 86150R107

1

Name of reporting person

Montrago Trustees Ltd

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CYPRUS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,256,181.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,256,181.00

11

Aggregate amount beneficially owned by each reporting person

2,256,181.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 86150R107

1

Name of reporting person

Skorpios Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CYPRUS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,256,181.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,256,181.00

11

Aggregate amount beneficially owned by each reporting person

2,256,181.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: Stoke Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 45 Wiggins Ave., Bedford, MASSACHUSETTS , 01730.
Item 1 Comment: This Amendment No. 6 (the "Amendment No. 6") is filed by Skorpios Trust, Montrago Trustees Limited ("Montrago Trustees"), Ezbon International Limited ("Ezbon") and Blue Horizon Enterprise Ltd. ("Blue Horizon" and, collectively, the "Reporting Persons") and amends the Schedule 13D filed by the Reporting Persons on June 30, 2021, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Persons on April 18, 2024, Amendment No. 2 to Schedule 13D filed by the Reporting Persons on September 23, 2024, Amendment No. 3 to Schedule 13D filed by the Reporting Persons on December 27, 2024, Amendment No. 4 to Schedule 13D filed by the Reporting Persons on June 6, 2025 and Amendment No. 5 to Schedule 13D filed by the Reporting Persons on June 23, 2025 (as amended, the "Schedule 13D"). The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 6 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the Schedule 13D.
Item 4.	Purpose of Transaction
	Item 4 is hereby amended and supplemented by adding the following: On August 22, 2025, Blue Horizon sold 1,000,000 Shares of the Issuer in an open market transaction at a price of $18.50 per share.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) is hereby amended and restated as follows: (a) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference.
(b)	Item 5(b) is hereby amended and restated as follows: (b) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference.
(c)	Item 5(c) is hereby amended and restated as follows: (c) The information reported in Item 4 is incorporated herein by reference. Other than as disclosed in that item, no transactions in the Shares have been effected by the Reporting Person during the past sixty (60) days.
(e)	As a result of the sale mentioned in Item 4 herein, the Reporting Persons ceased to be the beneficial owner of more than five percent of the Shares of the Issuer on August 22, 2025.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 - Joint Filing Agreement, dated as of August 26, 2025, by and among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Horizon Enterprise Ltd

Signature:	/s/ Eleni Constantinou Kyriacou
Name/Title:	Eleni Constantinou Kyriacou, Director
Date:	08/26/2025

Ezbon International Ltd

Signature:	/s/ Eleni Constantinou Kyriacou
Name/Title:	Eleni Constantinou Kyriacou, Director
Date:	08/26/2025

Montrago Trustees Ltd

Signature:	/s/ Androulla Papadopoulou
Name/Title:	Androulla Papadopoulou, Director
Date:	08/26/2025

Skorpios Trust

Signature:	/s/ Androulla Papadopoulou
Name/Title:	Androulla Papadopoulou, Director
Date:	08/26/2025

FAQ

What transaction is disclosed in the STOK Schedule 13D/A?

The filing reports that Blue Horizon sold 1,000,000 shares of Stoke Therapeutics in an open-market transaction at $18.50 per share on August 22, 2025.

Did the Reporting Persons remain above the 5% ownership threshold after the sale?

No. The filing states the Reporting Persons ceased to be beneficial owners of more than 5% of the issuer's common stock as a result of the sale.

How many shares outstanding were used to calculate percentages in the filing?

Percentages are calculated using 54,797,418 shares of common stock outstanding, as reported in the issuer's report for the period ending July 31, 2025.

Which reporting entities are named in this amendment?

The amendment is filed by Skorpios Trust; Montrago Trustees Ltd; Ezbon International Ltd; and Blue Horizon Enterprise Ltd.

Is there an agreement among the reporting persons filed as an exhibit?

Yes. Exhibit 1 is a Joint Filing Agreement dated August 26, 2025 among the Reporting Persons.